Below are the most recent publications written about "Stomach Neoplasms" by people in Profiles.
-
Zager Y, Goldes Y, Assaf D, Zilka N, Anteby R, Nevo Y, Barda L, Nevler A. Neutrophil to Lymphocyte Ratio in Patients Who Received Neoadjuvant Treatment before Gastrectomy. Isr Med Assoc J. 2023 May; 25(5):336-340.
-
Asif B, Sarvestani AL, Gamble LA, Samaranayake SG, Famiglietti AL, Fasaye GA, Quezado M, Miettinen M, Korman L, Koh C, Heller T, Davis JL. Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study. Lancet Oncol. 2023 04; 24(4):383-391.
-
Lamm R, Hewitt DB, Li M, Powell AC, Berger AC. Socioeconomic Status and Gastric Cancer Surgical Outcomes: A National Cancer Database Study. J Surg Res. 2022 07; 275:318-326.
-
Hitscherich KJ, Garg M, Petrelli NJ, Bennett JJ. Characteristics of Gastrointestinal Stromal Tumors incidentally discovered during abdominal surgery. Am J Surg. 2021 Nov; 222(5):983-988.
-
Curtin BF, Gamble LA, Schueler SA, Ruff SM, Quezado M, Miettinen M, Fasaye GA, Passi M, Hernandez JM, Heller T, Koh C, Davis JL. Enhanced endoscopic detection of occult gastric cancer in carriers of pathogenic CDH1 variants. J Gastroenterol. 2021 02; 56(2):139-146.
-
Lo W, Zhu B, Sabesan A, Wu HH, Powers A, Sorber RA, Ravichandran S, Chen I, McDuffie LA, Quadri HS, Beane JD, Calzone K, Miettinen MM, Hewitt SM, Koh C, Heller T, Wacholder S, Rudloff U. Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). J Med Genet. 2019 06; 56(6):370-379.
-
Nevo Y, Goldes Y, Barda L, Nadler R, Gutman M, Nevler A. Risk Factors for Complications of Total/Subtotal Gastrectomy for Gastric Cancer: Prospectively Collected, Based on the Clavien-Dindo Classification System. Isr Med Assoc J. 2018 05; 20(5):277-280.
-
Alvino DML, Chang DC, Adler JT, Noorbakhsh A, Jin G, Mullen JT. How Far Are Patients Willing to Travel for Gastrectomy? Ann Surg. 2017 06; 265(6):1172-1177.
-
Gerson JN, Skariah S, Denlinger CS, Astsaturov I. Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opin Investig Drugs. 2017 May; 26(5):531-540.
-
Prouet P, Giri S, Wiedower E, Fintel A, Yaghmour G, Lamb EP, Deneve J, Fleming M, Dickson P, Chandler JC, Martin MG. Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality. Anticancer Res. 2017 02; 37(2):813-817.